AU2015246037B2 - Methods of selectively treating asthma using IL-13 antagonists - Google Patents

Methods of selectively treating asthma using IL-13 antagonists Download PDF

Info

Publication number
AU2015246037B2
AU2015246037B2 AU2015246037A AU2015246037A AU2015246037B2 AU 2015246037 B2 AU2015246037 B2 AU 2015246037B2 AU 2015246037 A AU2015246037 A AU 2015246037A AU 2015246037 A AU2015246037 A AU 2015246037A AU 2015246037 B2 AU2015246037 B2 AU 2015246037B2
Authority
AU
Australia
Prior art keywords
ser
leu
val
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015246037A
Other languages
English (en)
Other versions
AU2015246037A1 (en
Inventor
Amy DAMASK
Steven Lewitzky
Michael Andreas ROTTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2015246037A1 publication Critical patent/AU2015246037A1/en
Priority to AU2018202260A priority Critical patent/AU2018202260B2/en
Application granted granted Critical
Publication of AU2015246037B2 publication Critical patent/AU2015246037B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47L—DOMESTIC WASHING OR CLEANING; SUCTION CLEANERS IN GENERAL
    • A47L5/00—Structural features of suction cleaners
    • A47L5/12—Structural features of suction cleaners with power-driven air-pumps or air-compressors, e.g. driven by motor vehicle engine vacuum
    • A47L5/22—Structural features of suction cleaners with power-driven air-pumps or air-compressors, e.g. driven by motor vehicle engine vacuum with rotary fans
    • A47L5/28—Suction cleaners with handles and nozzles fixed on the casings, e.g. wheeled suction cleaners with steering handle
    • A47L5/30—Suction cleaners with handles and nozzles fixed on the casings, e.g. wheeled suction cleaners with steering handle with driven dust-loosening tools, e.g. rotating brushes
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47L—DOMESTIC WASHING OR CLEANING; SUCTION CLEANERS IN GENERAL
    • A47L9/00—Details or accessories of suction cleaners, e.g. mechanical means for controlling the suction or for effecting pulsating action; Storing devices specially adapted to suction cleaners or parts thereof; Carrying-vehicles specially adapted for suction cleaners
    • A47L9/02—Nozzles
    • A47L9/04—Nozzles with driven brushes or agitators
    • A47L9/0427—Gearing or transmission means therefor
    • A47L9/0444—Gearing or transmission means therefor for conveying motion by endless flexible members, e.g. belts
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47L—DOMESTIC WASHING OR CLEANING; SUCTION CLEANERS IN GENERAL
    • A47L9/00—Details or accessories of suction cleaners, e.g. mechanical means for controlling the suction or for effecting pulsating action; Storing devices specially adapted to suction cleaners or parts thereof; Carrying-vehicles specially adapted for suction cleaners
    • A47L9/02—Nozzles
    • A47L9/04—Nozzles with driven brushes or agitators
    • A47L9/0455—Bearing means therefor
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47L—DOMESTIC WASHING OR CLEANING; SUCTION CLEANERS IN GENERAL
    • A47L9/00—Details or accessories of suction cleaners, e.g. mechanical means for controlling the suction or for effecting pulsating action; Storing devices specially adapted to suction cleaners or parts thereof; Carrying-vehicles specially adapted for suction cleaners
    • A47L9/02—Nozzles
    • A47L9/04—Nozzles with driven brushes or agitators
    • A47L9/0461—Dust-loosening tools, e.g. agitators, brushes
    • A47L9/0466—Rotating tools
    • A47L9/0477—Rolls
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47L—DOMESTIC WASHING OR CLEANING; SUCTION CLEANERS IN GENERAL
    • A47L9/00—Details or accessories of suction cleaners, e.g. mechanical means for controlling the suction or for effecting pulsating action; Storing devices specially adapted to suction cleaners or parts thereof; Carrying-vehicles specially adapted for suction cleaners
    • A47L9/10—Filters; Dust separators; Dust removal; Automatic exchange of filters
    • A47L9/16—Arrangement or disposition of cyclones or other devices with centrifugal action
    • A47L9/1683—Dust collecting chambers; Dust collecting receptacles
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47L—DOMESTIC WASHING OR CLEANING; SUCTION CLEANERS IN GENERAL
    • A47L9/00—Details or accessories of suction cleaners, e.g. mechanical means for controlling the suction or for effecting pulsating action; Storing devices specially adapted to suction cleaners or parts thereof; Carrying-vehicles specially adapted for suction cleaners
    • A47L9/32—Handles
    • A47L9/325—Handles for wheeled suction cleaners with steering handle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015246037A 2014-04-11 2015-04-08 Methods of selectively treating asthma using IL-13 antagonists Ceased AU2015246037B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018202260A AU2018202260B2 (en) 2014-04-11 2018-03-29 Methods of selectively treating asthma using IL-13 antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978604P 2014-04-11 2014-04-11
US61/978,604 2014-04-11
PCT/IB2015/052551 WO2015155710A1 (en) 2014-04-11 2015-04-08 Methods of selectively treating asthma using il-13 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202260A Division AU2018202260B2 (en) 2014-04-11 2018-03-29 Methods of selectively treating asthma using IL-13 antagonists

Publications (2)

Publication Number Publication Date
AU2015246037A1 AU2015246037A1 (en) 2016-10-06
AU2015246037B2 true AU2015246037B2 (en) 2018-04-12

Family

ID=52997487

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015246037A Ceased AU2015246037B2 (en) 2014-04-11 2015-04-08 Methods of selectively treating asthma using IL-13 antagonists
AU2018202260A Ceased AU2018202260B2 (en) 2014-04-11 2018-03-29 Methods of selectively treating asthma using IL-13 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018202260A Ceased AU2018202260B2 (en) 2014-04-11 2018-03-29 Methods of selectively treating asthma using IL-13 antagonists

Country Status (12)

Country Link
US (2) US10066267B2 (enExample)
EP (1) EP3129497B1 (enExample)
JP (2) JP2017513937A (enExample)
KR (1) KR20160138095A (enExample)
CN (1) CN106536754B (enExample)
AU (2) AU2015246037B2 (enExample)
BR (1) BR112016023238A2 (enExample)
CA (1) CA2943326A1 (enExample)
MX (1) MX2016013372A (enExample)
RU (1) RU2694980C2 (enExample)
TW (1) TW201542227A (enExample)
WO (1) WO2015155710A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279935B2 (en) * 2016-07-08 2022-03-22 Tak-Circulator Co, Ltd Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5
EP3476939A4 (en) 2016-07-08 2019-06-05 Tak-Circulator Co., Ltd. NUCLEIC ACID FOR INHIBITING THE EXPRESSION OF THE MEX3B GENE, MEX3B GENE EXPRESSION INHIBITOR, METHOD FOR INHIBITING MEX3B GENE EXPRESSION, PROPHYLACTIC ACID OR THERAPEUTIC FOR DISEASES THROUGH MEX3B GENE EXPRESSION
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
US10650928B1 (en) * 2017-12-18 2020-05-12 Clarify Health Solutions, Inc. Computer network architecture for a pipeline of models for healthcare outcomes with machine learning and artificial intelligence
US10811139B1 (en) 2018-06-13 2020-10-20 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and dynamic patient guidance
US11763950B1 (en) * 2018-08-16 2023-09-19 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and patient risk scoring
US11625789B1 (en) 2019-04-02 2023-04-11 Clarify Health Solutions, Inc. Computer network architecture with automated claims completion, machine learning and artificial intelligence
US11621085B1 (en) 2019-04-18 2023-04-04 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and active updates of outcomes
US11238469B1 (en) 2019-05-06 2022-02-01 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and risk adjusted performance ranking of healthcare providers
US10726359B1 (en) 2019-08-06 2020-07-28 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and automated scalable regularization
US10643751B1 (en) 2019-09-26 2020-05-05 Clarify Health Solutions, Inc. Computer network architecture with benchmark automation, machine learning and artificial intelligence for measurement factors
US10643749B1 (en) 2019-09-30 2020-05-05 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and automated insight generation
US11270785B1 (en) 2019-11-27 2022-03-08 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and care groupings
CN113215245A (zh) * 2021-05-21 2021-08-06 广州合一生物科技有限公司 一种用于儿童哮喘个体化用药的基因检测试剂盒及其应用
AU2021469707A1 (en) * 2021-10-22 2024-04-11 Illumina, Inc. Genotyping methods and systems
US12079230B1 (en) 2024-01-31 2024-09-03 Clarify Health Solutions, Inc. Computer network architecture and method for predictive analysis using lookup tables as prediction models

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6468528B1 (en) 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
US6645486B1 (en) 2000-01-25 2003-11-11 Ludwig Institute For Cancer Research Method of treatment with IL-9 conjugate
US7049069B2 (en) 2001-07-17 2006-05-23 University Of Florida Detecting and treating reproductive tract disorders
WO2003031587A2 (en) 2001-10-09 2003-04-17 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
JP2005512522A (ja) 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
WO2004082362A2 (en) 2003-03-18 2004-09-30 Nitto Denko Corporation Methods for extending amorphous photorefractive material lifetimes
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
EP2532677A1 (en) * 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
BRPI0710572A2 (pt) 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
KR20100014588A (ko) 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
PL2627673T3 (pl) 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REBECCA E SLAGER ET AL, "IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti IL-4 receptor antagonist", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 130, no. 2, pages 516 - 522.e4, (20120329) *

Also Published As

Publication number Publication date
CA2943326A1 (en) 2015-10-15
WO2015155710A1 (en) 2015-10-15
JP2017513937A (ja) 2017-06-01
RU2016144177A3 (enExample) 2018-12-13
AU2018202260B2 (en) 2019-12-12
TW201542227A (zh) 2015-11-16
CN106536754B (zh) 2021-04-16
US20200178741A1 (en) 2020-06-11
RU2694980C2 (ru) 2019-07-18
EP3129497A1 (en) 2017-02-15
EP3129497B1 (en) 2021-09-08
KR20160138095A (ko) 2016-12-02
CN106536754A (zh) 2017-03-22
WO2015155710A9 (en) 2016-05-19
MX2016013372A (es) 2017-01-26
RU2016144177A (ru) 2018-05-11
US20170029894A1 (en) 2017-02-02
BR112016023238A2 (pt) 2017-10-17
JP2020079241A (ja) 2020-05-28
US10066267B2 (en) 2018-09-04
AU2018202260A1 (en) 2018-04-26
AU2015246037A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
US11725246B2 (en) Methods of treating ophthalmic disorders
EP3129497B1 (en) Methods of selectively treating asthma using il-13 antagonists
JP2022033877A (ja) スタチンの応答および心血管疾患に関連する遺伝子多型、その検出方法ならびに使用
CN103201393B (zh) 使用多基因计分预测向晚期老年性黄斑变性的进展
US20070031846A1 (en) Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
JP2010533477A (ja) 水晶体落屑症候群および緑内障の診断、予後診断および治療における使用のためのマーカーとしての染色体１５ｑ２４上の遺伝的変異
AU2008205488A1 (en) Gene polymorphisms in VEGF and VEGF receptor 2 as markers for cancer therapy
AU2008205456A1 (en) Polymorphisms in the EGFR pathway as markers for cancer treatment
EP3102701A1 (en) Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
CN109311976A (zh) 使用TNFα拮抗剂治疗干眼症的方法
JP2008532499A (ja) 神経伝達物質輸送体をコードするヒトの自閉症感受性遺伝子及びその使用
US20190082912A1 (en) Methods Of Selectively Treating Asthma Using IL-13 Antagonists
US20230331863A1 (en) Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
MXPA06014127A (es) Biomarcadores para la prediccion de respuesta al tratamiento con clozapina.
EP2483424B1 (en) Method for the diagnosis/prognosis of age-related macular degeneration
JP2008537486A (ja) 膜貫通タンパク質をコード化するヒトの自閉症感受性遺伝子およびその使用
HK1182142A (en) Predicting progression to advanced age-related macular degeneration using a polygenic score
HK1182142B (en) Predicting progression to advanced age-related macular degeneration using a polygenic score

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired